<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002113</url>
  </required_header>
  <id_info>
    <org_study_id>213A</org_study_id>
    <secondary_id>R-0202</secondary_id>
    <nct_id>NCT00002113</nct_id>
  </id_info>
  <brief_title>A Pilot Study of Fluconazole Plus Flucytosine for the Treatment of AIDS Patients With Acute Cryptococcal Meningitis.</brief_title>
  <official_title>A Pilot Study of Fluconazole Plus Flucytosine for the Treatment of AIDS Patients With Acute Cryptococcal Meningitis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To evaluate and estimate the safety and efficacy of the combination of fluconazole and&#xD;
      flucytosine as treatment for acute cryptococcal meningitis in patients with AIDS.&#xD;
&#xD;
      Fluconazole and flucytosine have different mechanisms of action. Since fluconazole has not&#xD;
      been associated with hematologic suppression and does not produce renal impairment that can&#xD;
      result in higher serum flucytosine levels, this combination may be better tolerated than is&#xD;
      amphotericin B plus flucytosine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fluconazole and flucytosine have different mechanisms of action. Since fluconazole has not&#xD;
      been associated with hematologic suppression and does not produce renal impairment that can&#xD;
      result in higher serum flucytosine levels, this combination may be better tolerated than is&#xD;
      amphotericin B plus flucytosine.&#xD;
&#xD;
      Patients in each cohort receive a lower dose of fluconazole alone or in combination with&#xD;
      flucytosine, or a higher dose of fluconazole alone. Doses in subsequent cohorts are escalated&#xD;
      if safety data in the previous cohort is satisfactory. Patients are evaluated weekly for the&#xD;
      first 4 weeks and every 2 weeks thereafter. Therapy continues until 8 weeks after the CSF&#xD;
      becomes culture negative, up to a maximum of 26 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>64</enrollment>
  <condition>Meningitis, Cryptococcal</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flucytosine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluconazole</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Antiviral therapy (AZT, DHPG).&#xD;
&#xD;
          -  Prophylaxis for Pneumocystis carinii pneumonia.&#xD;
&#xD;
          -  Treatment for intercurrent opportunistic infection.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Radiation therapy for mucocutaneous Kaposi's sarcoma.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  AIDS.&#xD;
&#xD;
          -  Evidence of Cryptococcal neoformans in culture or lumbar CSF OR clinical and CSF&#xD;
             findings compatible with cryptococcal meningitis.&#xD;
&#xD;
          -  No evidence of acute or chronic meningitis of any etiology other than cryptococcosis.&#xD;
&#xD;
          -  Life expectancy of at least 2 weeks.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Prior antiviral therapy (AZT, DHPG).&#xD;
&#xD;
          -  Prophylaxis for Pneumocystis carinii pneumonia.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Relapsing on maintenance triazole therapy for cryptococcal meningitis.&#xD;
&#xD;
          -  Unable to take oral medication.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Concomitant use of any antifungal agent other than study drug.&#xD;
&#xD;
        Patients with the following prior conditions are excluded:&#xD;
&#xD;
        History of allergy to or intolerance of imidazoles, azoles, or flucytosine.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  More than 1 mg/kg amphotericin B.&#xD;
&#xD;
          -  Systemic antifungal agents within 7 days prior to study entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Los Angeles County - USC Med Ctr</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCI Med Ctr</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92668</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD Med Ctr - Owen Clinic</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>921038681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Larsen RA, Bozzette SA, Jones BE, Haghighat D, Leal MA, Forthal D, Bauer M, Tilles JG, McCutchan JA, Leedom JM. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis. 1994 Oct;19(4):741-5. doi: 10.1093/clinids/19.4.741.</citation>
    <PMID>7803641</PMID>
  </reference>
  <verification_date>April 1996</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Meningitis</keyword>
  <keyword>Cryptococcosis</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Fluconazole</keyword>
  <keyword>Flucytosine</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningitis, Cryptococcal</mesh_term>
    <mesh_term>Meningitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluconazole</mesh_term>
    <mesh_term>Flucytosine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

